BioInvent International AB (publ) (LON:0H22)
 33.50
 +3.05 (10.02%)
  At close: Oct 30, 2025
LON:0H22 Revenue
BioInvent International AB had revenue of 3.32M SEK in the quarter ending September 30, 2025, a decrease of -73.98%. This brings the company's revenue in the last twelve months to 244.85M, up 533.73% year-over-year. In the year 2024, BioInvent International AB had annual revenue of 44.69M, down -37.47%.
Revenue (ttm) 
 244.85M SEK
Revenue Growth 
 +533.73%
P/S Ratio 
 9.14
Revenue / Employee 
 2.15M SEK
Employees 
 114
Market Cap 
176.70M GBP
Revenue Chart
* This company reports financials in SEK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 44.69M | -26.78M | -37.47% | 
| Dec 31, 2023 | 71.46M | -254.67M | -78.09% | 
| Dec 31, 2022 | 326.13M | 306.74M | 1,582.45% | 
| Dec 31, 2021 | 19.38M | -127.99M | -86.85% | 
| Dec 31, 2020 | 147.37M | 53.63M | 57.21% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| AstraZeneca | 41.24B | 
| GSK plc | 31.63B | 
| Haleon | 11.02B | 
| Smith & Nephew | 4.33B | 
| Hikma Pharmaceuticals | 2.35B | 
| ConvaTec Group | 1.72B | 
| Spire Healthcare Group | 1.55B | 
| Genus | 672.80M |